In light of the all-clear for Enfamil in the bacteria case that sent Mead Johnson (MJN +3.8%)...

|About: Mead Johnson Nutrition Company (MJN)|By:, SA News Editor

In light of the all-clear for Enfamil in the bacteria case that sent Mead Johnson (MJN +3.8%) shares tumbling, William Blair says the stock is at "a level we view as attractive in light of the company's attractive long-term growth and return characteristics," based on penetration and consumption growth opportunities in emerging markets and a potential recovery in the U.S. birthrate over time.